TAKARA BIO, The Current Fiscal Year Ordinary Profit Revised Downward to an Unexpected 12% Decrease

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Feb 13, 2025 3:30 pm JST Earnings

4974 TAKARA BIO INC. 【J-GAAP】

Earnings Report

TAKARA BIO INC. <4974> [TSE Prime] announced its financial results after the market closed on February 13th (15:30). The consolidated ordinary profit/loss for the cumulative third quarter of the fiscal year ending March 2025 (April to December) turned into a loss of 1.25 billion yen (compared to a profit of 0.58 billion yen in the same period last year).

In addition, the full-year consolidated ordinary profit has decreased 42.3%, from the previous forecast of 5.2 billion yen to 3 billion yen (compared to 3.4 billion yen in the previous period). This changes the outlook from an anticipated profit increase to a projection of a 11.9% decrease in profit.

Based on the full-year plan announced by the company after the downward revision, our estimate of the consolidated ordinary profit for the October to March period (2H) has decreased 47.3%, from the previous forecast of 4.65 billion yen to 2.45 billion yen (compared to 1.8 billion yen in the same period of the previous year), leading to a reduction in the profit growth rate from 2.6 times to 35.6%.

In the most recent three-month period, from October to December (3Q), the consolidated ordinary loss expanded to a loss of 1.8 billion yen (compared to a loss of 1.01 billion yen in the same period last year). The operating profit/loss margin drastically worsened from -10.1% in the same period last year to -19.8%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	60,206	19,403	19,480	14,595	121.2	94.2	Feb 9, 2023	J-GAAP
Apr - Dec, 2023	29,734	336	586	154	1.3	17.2	Feb 14, 2024	J-GAAP
Apr - Dec, 2024	29,282	-1,473	-1,255	-1,378	-11.5	ー	Feb 13, 2025	J-GAAP
YoY	-1.5%	－	－	－	－

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	29,142	4,583	4,651	2,887	24.0	17	Nov 8, 2024	J-GAAP
Oct - Mar, 2024 New	25,742	2,583	2,451	487	4.0	17	Feb 13, 2025	J-GAAP
Revision Rate	-11.7%	-43.6%	-47.3%	-83.1%	-83.2%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	48,900	5,000	5,200	3,400	28.2	17	May 10, 2024	J-GAAP
Mar, 2025 New	45,500	3,000	3,000	1,000	8.3	17	Feb 13, 2025	J-GAAP
Revision Rate	-7.0%	-40.0%	-42.3%	-70.6%	-70.6%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	24,389	1,593	1,807	396	3.3	17	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	25,742	2,583	2,451	487	4.0	17	Feb 13, 2025	J-GAAP
YoY	+5.5%	+62.1%	+35.6%	+23.0%	+22.8%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	78,142	20,541	20,682	16,012	133.0	42	May 11, 2023	J-GAAP
Mar, 2024	43,505	3,003	3,405	1,480	12.3	17	May 10, 2024	J-GAAP
Mar, 2025 Guidance	45,500	3,000	3,000	1,000	8.3	17	Feb 13, 2025	J-GAAP
YoY	+4.6%	-0.1%	-11.9%	-32.4%	-32.5%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	10,618	-1,074	-1,012	-930	-7.7	-10.1	Feb 14, 2024	J-GAAP
Jan - Mar, 2024	13,771	2,667	2,819	1,326	11.0	19.4	May 10, 2024	J-GAAP
Apr - Jun, 2024	8,493	-1,634	-1,498	-1,047	-8.7	-19.2	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	11,265	2,051	2,047	1,560	13.0	18.2	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	9,524	-1,890	-1,804	-1,891	-15.7	-19.8	Feb 13, 2025	J-GAAP
YoY	-10.3%	-76.0%	-78.3%	-103.3%	-103.2%